Blood levels of specific antibodies that target the muscle-specific tyrosine kinase (MuSK) may be biomarkers of disease severity and treatment response in people with myasthenia gravis (MG) who are positive for anti-MuSK antibodies. A study finds that high levels of MuSK-IgG4 — an anti-MuSK antibody subclass – were associated…

Treatment with the immunosuppressant Prograf (tacrolimus) within one year of the onset of juvenile myasthenia gravis (JMG) was found to be safe and effective in a study of pediatric patients in China. Patients who were started on Prograf earlier after JMG onset were significantly more likely to achieve…

The use of myasthenia gravis (MG) treatments did not increase COVID-19 infection risk or severity, according to a new study of Chinese patients with both generalized myasthenia gravis (gMG) and ocular types of MG. In fact, continuing treatment with nonspecific nonsteroidal immunosuppressants and antibody therapies during infection…

Johnson & Johnson has submitted an application to the European Medicines Agency (EMA) seeking approval of nipocalimab to treat people with generalized myasthenia gravis (gMG). The request includes gMG patients who are positive for MG-causing autoantibodies targeting acetylcholine receptors (AChRs), muscle-specific tyrosine (MuSK), and low-density lipoprotein…

Both Soliris (eculizumab) and Vyvgart (efgartigimod alfa-fcab) rapidly eased disease severity among adults with generalized myasthenia gravis (gMG), according to a real-world study that compared the two therapies. Soliris outperformed Vyvgart in its ability to reduce gMG severity and corticosteroid dose over a year of treatment, however.

Using a combination of two standardized assessment tools may be better than the classification process now in place in predicting the outcomes of people with a thymoma, or thymus tumor, associated with myasthenia gravis (MG), a new study suggests. The newly proposed system, from researchers in China, would classify…

The first patient has been dosed in a Phase 3 clinical trial that’s assessing the safety and efficacy of oral cladribine for treating generalized myasthenia gravis (gMG). The study, called MyClad (NCT06463587), is intended to test whether short courses of cladribine treatment can outperform a placebo at easing…

Mycophenolate mofetil (MMF) safely and effectively controlled symptoms of generalized myasthenia gravis (gMG) in patients switching from azathioprine, another immunosuppressive agent, a study finds. “This study supports the efficacy and safety of MMF in the treatment of MG,” wrote the study’s researchers, who said more research with a…

Combining Vyvgart (efgartigimod) with steroid therapy resolved a myasthenic crisis, a potentially life-threatening complication of myasthenia gravis (MG) marked by severe breathing problems, in a 70-year-old Japanese woman with generalized MG (gMG), a case study shows. The combined therapy successfully treated the myasthenic crisis in the absence…

Johnson & Johnson has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of nipocalimab to treat people with generalized myasthenia gravis (gMG). The application covers gMG patients who are positive for disease-causing antibodies against acetylcholine receptors (AChRs), muscle-specific kinase (MuSK), and low…